[1]赵苗苗,魏敬芝,张 昆.纤维胶凝蛋白3在反复上呼吸道感染患儿血清中的表达及意义[J].陕西医学杂志,2022,51(6):733-736.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.022]
　ZHAO Miaomiao,WEI Jingzhi,ZHANG Kun.Expression and significance of serum ficolin-3 in children with recurrent upper respiratory tract infection[J].,2022,51(6):733-736.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.022]
点击复制

纤维胶凝蛋白3在反复上呼吸道感染患儿血清中的表达及意义
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
51
期数:
2022年6期
页码:
733-736
栏目:
临床检验
出版日期:
2022-06-05

文章信息/Info

Title:
Expression and significance of serum ficolin-3 in children with recurrent upper respiratory tract infection
作者:
赵苗苗; 魏敬芝; 张 昆
(汉中市中心医院儿科,陕西 汉中 723099)
Author(s):
ZHAO Miaomiao; WEI Jingzhi; ZHANG Kun
(Department of Pediatrics,Hanzhong Central Hospital,Hanzhong 723099,China)
关键词:
反复上呼吸道感染;  纤维胶凝蛋白3;  体液免疫功能;  儿童;  相关性;  预测价值
Keywords:
Recurrent upper respiratory tract infection;  Ficolin-3;  Humoral immune function;  Children;  Correlation;  Predictive value
分类号:
R 56
DOI:
DOI:10.3969/j.issn.1000-7377.2022.06.022
文献标志码:
A
摘要:
目的:观察反复上呼吸道感染患儿血清中纤维胶凝蛋白3(FCN3)的表达情况,并分析其与患儿体液免疫功能的相关性及对疾病的预测价值。方法:选择反复上呼吸道感染患儿126例为观察组,选择同时期体检结果健康的儿童120例为对照组。采用酶联免疫吸附实验测定两组受试者及观察组患儿治疗前后血清FCN3、体液免疫指标(IgA、IgG、IgM)的表达水平。采用Pearson分析法分析反复上呼吸道感染患儿血清FCN3与IgA、IgG、IgM的相关性。采用受试者工作特征(ROC)曲线分析血清FCN3表达对反复上呼吸道感染发病的预测价值。结果:观察组患儿血清FCN3、IgA、IgG、IgM表达水平低于对照组(均P<0.05)。患儿治疗后血清中FCN3表达水平及免疫指标水平较治疗前提高(均P<0.05)。Pearson分析结果显示,FCN3表达水平与IgA、IgG、IgM呈正相关(r=0.531、0.436、0.499,均P<0.05)。ROC曲线分析显示,血清中FCN3预测反复上呼吸道感染发生的曲线下面积为0.752(95%CI:0.688～0.815),截断值为15.723 μg/ml,敏感度为96.0%,特异度为51.7%。结论:反复上呼吸道感染患儿血清中FCN3呈低表达,且与IgA、IgG、IgM的表达水平呈正相关,是预测反复上呼吸道感染较为良好的指标。
Abstract:
Objective:To observe the expression of ficolin-3(FCN3)in serum of children with recurrent upper respiratory tract infection,and to analyze its correlation with humoral immune function and its predictive value for disease.Methods: A total of 126 children with recurrent upper respiratory tract infection and 120 healthy children in the same period were selected as observation group and control group,respectively.Enzyme-linked immunosorbent assay was used to measure the expression levels of FCN3 and humoral immune indexes(IgA,IgG,IgM)in serum of the two groups and the observation group before and after treatment.Pearson analysis was used to analyze the correlation between serum FCN3 and IgA,IgG and IgM in children with recurrent upper respiratory tract infection.Receiver operating characteristic(ROC)curve was used to analyze the predictive value of serum FCN3 expression for recurrent upper respiratory tract infections.Results:The expression levels of FCN3,IgA,IgG and IgM in the observation group were lower than those in the control group(all P<0.05).After treatment,the expression level of FCN3 and the levels of immune indexes in serum were higher than those before treatment(all P<0.05).Pearson analysis showed that FCN3 expression level was positively correlated with IgA,IgG and IgM(r=0.531,0.436 and 0.499,all P<0.05).ROC curve analysis showed that the area under the curve of FCN3 in serum to predict the occurrence of recurrent upper respiratory tract infection was 0.752(95%CI:0.688 to 0.815),cut-off value was 15.723 μg/ml,sensitivity was 96.0%,and specificity was 51.7%.Conclusion:FCN3 expression in serum of children with recurrent upper respiratory tract infection is low and positively correlated with the expression levels of IgA,IgG and IgM,which is a good predictor of recurrent upper respiratory tract infection.

参考文献/References:

[1] 李 政,蒋晶晶,巫 波,等.反复呼吸道感染患儿血清维生素A、E和体液免疫水平变化及临床意义[J].成都医学院学报,2019,14(4):463-466.
[2] 陈庆庆,张 骠.张骠教授治疗小儿反复呼吸道感染经验[J].陕西中医,2019,40(7):940-943.
[3] 刘子菁,欧书腾,刘远威,等.259例反复呼吸道感染婴幼儿血清免疫球蛋白水平分析[J].医学理论与实践,2019,32(8):1234-1236.
[4] 靳 煜,陈海英.Ficolins与类风湿关节炎的研究进展[J].中华风湿病学杂志,2016,20(7):492-495.
[5] 朱素杰,范红娟.EB病毒感染儿童血清纤维胶凝蛋白3、sTRAIL的表达水平及意义[J].武警后勤学院学报:医学版,2020,29(4):27-31.
[6] 周 颖.血清候选标志物SAA1和FCN3的发现与验证[D].湛江:广东医科大学,2016.
[7] 中华医学会儿科学分会呼吸学组,《中华儿科杂志》编辑委员会.反复呼吸道感染的临床概念和处理原则[J].中华儿科杂志,2008,46(2):108-110.
[8] 胡海赟,王 春,姚剑杰,等.儿童反复呼吸道感染病原菌临床分布及危险因素研究[J].陕西医学杂志,2019,48(6):781-783,809.
[9] 桂 莹.芪双抗感汤联合西药治疗小儿反复呼吸道感染疗效观察[J].陕西中医,2017,38(5):634-635,669.
[10] 郭 茹,杨湘峰,李 芳,等.反复呼吸道感染患儿血清Vit A、Vit D、Vit E水平变化及与细胞免疫功能的相关性分析[J].临床肺科杂志,2021,26(9):1366-1370.
[11] Tarantino V,Savaia V,Dagostino R,et al.Bacteriotherapy in children with recurrent upper respiratory tract infections[J].Eur Rev Med Pharmacol Sci,2019,23(1):39-43.
[12] 白思远,郭素香,陈 慧.儿童反复呼吸道感染危险因素的Meta分析[J].中华医院感染学杂志,2021,31(12):1811-1816.
[13] 宋元玉.反复呼吸道感染患儿创伤后成长情况及影响因素分析[J].中华现代护理杂志,2019,25(10):1299-1302.
[14] 刘萍萍,谢宝强,业晓青,等.反复呼吸道感染儿童细胞免疫与体液免疫研究[J].中国预防医学杂志,2019,20(2):136-138.
[15] 刘艳杰,丁殿帅,李 静.反复呼吸道感染儿童维生素A缺乏状况与炎症因子、免疫功能指标相关性分析[J].陕西医学杂志,2021,50(7):858-860.
[16] Munteanu AN,Surcel M,Huic RI,et al.Peripheral immune cell markers in children with recurrent respiratory infections in the absence of primary immunodeficiency[J].Exp Ther Med,2019,18(3):1693-1700.
[17] Pasternak G,Lewandowicz-Uszyńska A,Pentos K.Disorders of humoral immunity in children with IgG subclass deficiency and recurrent respiratory infections[J].Adv Exp Med Biol,2018,1108:99-106.
[18] 林桐梅,高 笛.原发性高血压患者血清纤维蛋白胶凝素3水平与颈动脉粥样硬化的相关性研究[J].中华老年心脑血管病杂志,2019,21(6):600-604.
[19] 王世雄,聂 浩.纤维胶凝蛋白(ficolin)与感染性疾病[J].中国人兽共患病学报,2019,35(1):76-80,90.
[20] Man-Kupisinska A,Michalski M,Maciejewska A,et al.A new ligand-based method for purifying active human plasma-derived ficolin-3 complexes supports the phenomenon of crosstalk between pattern-recognition molecules and immunoglobulins[J].PLoS One,2016,11(5):e0156691.
[21] Michalski M,St-Swierzko A,Lukasiewicz J,et al.Ficolin-3 activity towards the opportunistic pathogen,Hafnia alvei[J].Immunobiology,2015,220(1):117-123.
[22] Plawecki M,Lheritier E,Clavarino G,et al.Association between the presence of autoantibodies targeting ficolin-3 and active nephritis in patients with systemic lupus erythematosus[J].PLoS One,2016,11(9):e0160879.

相似文献/References:

[1]何阶德,梁 航,黄 朦,等.血清C肽、自噬关键分子酵母Atg6同系物、纤维胶凝蛋白3在2型糖尿病肾病患者中的表达变化及其预测价值研究[J].陕西医学杂志,2024,(3):327.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.008]
　HE Jiede,LIANG Hang,HUANG Meng,et al.Changes and predictive value of serum C peptide,ATG6 autophagy related 6 homolog and Ficolin-3 in type 2 diabetic nephropathy[J].,2024,(6):327.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.008]

备注/Memo

备注/Memo:
基金项目:陕西省重点研发计划项目(2019SF-148)
更新日期/Last Update: 2022-06-06